Cinaron Plus

Cerebral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of cerebral vascular spasms and arteriosclerosis such as: dizziness, ear buzzing (tinnitus), vascular headache, unsociability and irritability, fatigue, sleep rhythm disorders such as premature awakening, involutional depressions, loss of memory and lack of concentration, incontinence and other disorders due to aging. ... Read moreCerebral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of cerebral vascular spasms and arteriosclerosis such as: dizziness, ear buzzing (tinnitus), vascular headache, unsociability and irritability, fatigue, sleep rhythm disorders such as premature awakening, involutional depressions, loss of memory and lack of concentration, incontinence and other disorders due to aging. Sequelae of cerebral and cranial trauma. Postapoplectic disorders. Migraine. Peripheral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of vascular spasms and arteriosclerosis (obliterating arteritis, thromboangitis obliterans, Raynaud's disease, diabetes, acrocyanosis pernio, etc.) such as intermittent claudication, trophic disturbances, pregangrene, trophic and varicose ulcers, paraesthesia, nocturnal cramps, cold extremities.Disorders of balance: Prophylaxis and maintenance therapy for symptoms of labyrinthine arteriosclerosis; vestibular irritability; Meniere's syndrome such as vertigo, dizziness, giddiness, syncopal attacks, tinnitus, nystagmus, nausea and vomiting. Prophylaxis of motion sickness.

Anti vertigo drugs

Cinnarizine provides faster relief of various symptoms of cerebral and peripheral circulation disorders and prevents attacks of vascular headache such as migraine. Cinnarizine normalizes cerebral circulation time and curves and improves cerebral irrigation in patients suffering from cerebral circulation disorders. Cinnarizine normalizes arterial pulsations in patients suffering from vasospastic disorders (Raynaud's disease). Cinnarizine significantly increases the rate of inflow of pulsations and the blood flow in the most affected limbs as well as the walking distance of patients suffering from intermittent claudication. Cinnarizine reduces the healing time of crural ulcers. Cinnarizine reduces or eliminates symptoms of vestibular disturbances like, vertigo, tinnitus and autonomic manifestations (nausea, vomiting, pallor and cold extremities) and reduces or prevents future episodes.Dimenhydrinate acts as antihistamine with anti-cholinergic properties.The substance exhibits the anti-emetic & anti vertigo effects through influencing the chemoreceptor trigger zone.

Usual adult dose: 1 tablet three times daily to be taken with liquid after meal or as advised by the physician. Children (under the age of 18): Not recommended.

Adults: 1 tablet three times daily, to be taken after meals. Children andadolescents under the age of 18 years: Not recommended Elderly: Dosage as for adults.

Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of Cinnarizine and Dimenhydrinate. Therefore, it is advisable to avoid these drugs while taking Cinnarizine and Dimenhydrinate.

Cinnarizine and Dimenhydrinate should not be used by patients with severe hepatic impairment. Cinnarizine and Dimenhydrinate is contra-indicated in patients with known hypersensitivity to the active substances or to any of the excipients. Cinnarizine and Dimenhydrinate should not be used in patients with angle-closure glaucoma, convulsions, suspicion of raised intracranial pressure, and alcohol abuse or urine retention due to urethroprostatic disorders.

Drowsiness, dry mouth, headache, and stomach pain may occur. Rare side effects are impaired vision, allergic reactions, light sensitivity, and difficulty in urinating. Other possible reactions which may occur: weight gain, constipation, tightness of the chest, jaundice, worsening of angle-closure glaucoma, uncontrollable movements, unusual excitement and restlessness, severe skin reactions.

The safety of the combination of Cinnarizine & Dimenhydrinate in human pregnancy has not been established. The combination of Cinnarizine & Dimenhydrinate is excreted in human breast milk and should not be taken by women who are breast feeding.

Cinnarizine and Dimenhydrinate do not reduce blood pressure significantly; however, it should be used with caution in hypotensive patients. Cinnarizine and Dimenhydrinate should be taken after meals to minimize any gastric irritation. Caution should be exercised when administering Cinnarizine and Dimenhydrinate to patients with Parkinson’s disease.

Drowsiness, dizziness and ataxia with anticholinergic effects such as dry mouth, flushing of the face, dilated pupils, tachycardia, pyrexia, headache and urinary retention. General supportive measures should be used to treat respiratory insufficiency or circulatory failure. Gastric lavage with isotonic sodium chloride solution is recommended.

Store in a cool (below 30°C) and dry place. Keep away from light and out of reach of children.

Anti vertigo drugs

This contains two active ingredients Cinnarizine and Dimenhydrinate. The two substances belong to different groups of medicines. Cinnarizine is part of a group called calcium antagonists. Dimenhydrinate belongs to a group called antihistamines. Both substances work by reducing symptoms of vertigo (a feeling of dizziness or spinning) and nausea (feeling sick). The combination product is more effective than the individual compounds.

Dimenhydrinate and cinnarizine should not be used during pregnancy and lactation.